RxDoctor Payments Data

Scott Simecek, DO

Pulmonary Disease · Clarkston, MINPI 1104865765

Payments from drug & device makers

$16,247in general payments, 2019–2025

Across 476 payments — averaging $34.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$7K
  • AstraZeneca$2K
  • GSK$1K
  • Boehringer Ingelheim$998
  • Regeneron Healthcare Solutions, Inc.$600
  • Grifols USA, LLC$445
  • plus $4K from 35 others

What the payments were for

  • Travel & lodging$1,0637%
  • Food & beverage$9,14656%
  • Education$6,03837%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,247 in reported general payments places this provider in the 80th percentile of 463 pulmonary disease providers in Michigan.

See all pulmonary disease providers in Michigan

Medicare billing

Part B allowed, 2024
$154,280
Medicare patients
493
Services billed
1,540

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate35$458,913
Trelegy ElliptaFluticasone/Umeclidin/Vilanter413$455,500
Tasimelteon11$225,535
Breo ElliptaFluticasone/Vilanterol184$99,426
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr109$70,841
Breztri AerosphereBudesonide/Glycopyr/Formoterol42$38,942
Spiriva RespimatTiotropium Bromide38$36,591
EliquisApixaban26$22,411
Stiolto RespimatTiotropium Br/Olodaterol Hcl16$17,125
Albuterol Sulfate HfaAlbuterol Sulfate379$14,358
Fluticasone-SalmeterolFluticasone Propion/Salmeterol64$13,893
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate30$11,169
SymbicortBudesonide/Formoterol Fumarate25$11,068
Varenicline Tartrate31$10,509
Combivent RespimatIpratropium/Albuterol Sulfate12$8,235

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$1,389$625,767706 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat$998$520,864101 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,518$50,01067 claims
PfizerEliquis$14$22,41126 claims
MerckDulera$102$6,11315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 463 pulmonary disease providers in Michigan.

Other pulmonary disease in Clarkston

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →